Search

Displaying results 1321 - 1330 of 9129 in total
  1. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    As a liposomal formulation, mifamurtide demonstrates an enhanced tumoricidal effect and improved safety profile [A31745]. Mifamurtide is marketed in Europe as Mepact for intravenous infusion. … Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP).

  2. Drug

    Oleic Acid

    go.drugbank.com/drugs/DB04224
    ApprovedInvestigationalVet approved

    An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent.

  3. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

  4. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form .

  5. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.

  6. Drug

    Human papillomavirus type 16 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10301
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 16 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.

    Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADET
  7. Drug

    Human papillomavirus type 18 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10302
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 18 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.

    Mixtures: GARDASIL 0.5 ML IM ENJEKSİYON İÇİN SÜSPANSİYON İÇEREN FLAKON, CERVARIX 0,5 ML IM ENJEKSIYON ICIN SUSPANSIYON ICEREN FLAKON, 1 ADET
  8. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor]. … [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS.

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  9. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Expanded cells are then suspended in a cell medium. … Azficel-T is marketed in the US as Laviv for intradermal injection.

  10. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. … [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]